Physician profile
Alan Beyer
NPI 1104853134
$2,110.90
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $60.55 · 2022: $1,898 · 2023: $14.56 · 2024: $18.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Djo, LLC | $1,840.00 | 2022 | |
| Depuy Synthes Sales INC. | $141.92 | 2019-2020 | |
| Dynasplint Systems INC. | $57.79 | 2022 | |
| Zimmer Biomet Holdings, INC. | $33.55 | 2023-2024 | Gel-One Cross-Linked Hyaluronate |
| Bone Support INC. | $19.83 | 2020 | |
| Arthrosurface Incorporated | $17.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Beyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.